Sepsis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Sepsis - Pipeline Review, H1 2019’, provides an overview of the Sepsis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sepsis

- The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects

- The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Sepsis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sepsis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adrenomed AG

Am-Pharma BV

Arch Biopartners Inc

Asahi Kasei Pharma Corp

Atox Bio Ltd

Aurigene Discovery Technologies Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cell2B ...

Adrenomed AG

Am-Pharma BV

Arch Biopartners Inc

Asahi Kasei Pharma Corp

Atox Bio Ltd

Aurigene Discovery Technologies Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cell2B Advanced Therapeutics SA

Cells for Cells SA

China Grand Pharmaceutical and Healthcare Holdings Ltd

Chongqing Zhifei Biological Products Co Ltd

Cilian AG

Cynata Therapeutics Ltd

CytaCoat AB

Dr. Franz Kohler Chemie GmbH

Endacea Inc

Enlivex Therapeutics Ltd

Enzychem Lifesciences Corp

Evec Inc

Immunwork Inc

InflaRx NV

Integrated BioTherapeutics Inc

Lead Discovery Center GmbH

MetrioPharm AG

Microbiotix Inc

Mochida Pharmaceutical Co Ltd

Nosopharm SAS

OncoImmune Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

ProThera Biologics Inc

Q BioMed Inc

Ra Pharmaceuticals Inc

Recce Ltd

Regeneron Pharmaceuticals Inc

Ribomic Inc

Rimonyx Pharmaceuticals Ltd

SciClone Pharmaceuticals Inc

SetLance srl

Shionogi & Co Ltd

SK Biopharmaceuticals Co Ltd

Syntiron LLC

Takeda Pharmaceutical Co Ltd

Therakind Ltd

Therashock LLC

Vascular BioSciences

Table of Contents

Table of Contents

Introduction

Sepsis – Overview

Sepsis – Therapeutics Development

Sepsis – Therapeutics Assessment

Sepsis – Companies Involved in Therapeutics Development

Sepsis – Drug Profiles

Sepsis – Dormant Projects

Sepsis ...

Table of Contents

Introduction

Sepsis – Overview

Sepsis – Therapeutics Development

Sepsis – Therapeutics Assessment

Sepsis – Companies Involved in Therapeutics Development

Sepsis – Drug Profiles

Sepsis – Dormant Projects

Sepsis – Discontinued Products

Sepsis – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Sepsis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Sepsis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Sepsis – Pipeline by Adrenomed AG, H1 2019

Sepsis – Pipeline by Am-Pharma BV, H1 2019

Sepsis – Pipeline by Arch Biopartners Inc, H1 2019

Sepsis – Pipeline by Asahi Kasei Pharma Corp, H1 2019

Sepsis – Pipeline by Atox Bio Ltd, H1 2019

Sepsis – Pipeline by Aurigene Discovery Technologies Ltd, H1 2019

Sepsis – Pipeline by Boehringer Ingelheim GmbH, H1 2019

Sepsis – Pipeline by Bristol-Myers Squibb Co, H1 2019

Sepsis – Pipeline by Cell2B Advanced Therapeutics SA, H1 2019

Sepsis – Pipeline by Cells for Cells SA, H1 2019

Sepsis – Pipeline by China Grand Pharmaceutical and Healthcare Holdings Ltd, H1 2019

Sepsis – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2019

Sepsis – Pipeline by Cilian AG, H1 2019

Sepsis – Pipeline by Cynata Therapeutics Ltd, H1 2019

Sepsis – Pipeline by CytaCoat AB, H1 2019

Sepsis – Pipeline by Dr. Franz Kohler Chemie GmbH, H1 2019

Sepsis – Pipeline by Endacea Inc, H1 2019

Sepsis – Pipeline by Enlivex Therapeutics Ltd, H1 2019

Sepsis – Pipeline by Enzychem Lifesciences Corp, H1 2019

Sepsis – Pipeline by Evec Inc, H1 2019

Sepsis – Pipeline by Immunwork Inc, H1 2019

Sepsis – Pipeline by InflaRx NV, H1 2019

Sepsis – Pipeline by Integrated BioTherapeutics Inc, H1 2019

Sepsis – Pipeline by Lead Discovery Center GmbH, H1 2019

Sepsis – Pipeline by MetrioPharm AG, H1 2019

Sepsis – Pipeline by Microbiotix Inc, H1 2019

Sepsis – Pipeline by Mochida Pharmaceutical Co Ltd, H1 2019

Sepsis – Pipeline by Nosopharm SAS, H1 2019

Sepsis – Pipeline by OncoImmune Inc, H1 2019

Sepsis – Pipeline by Ono Pharmaceutical Co Ltd, H1 2019

Sepsis – Pipeline by Opsona Therapeutics Ltd, H1 2019

Sepsis – Pipeline by ProThera Biologics Inc, H1 2019

Sepsis – Pipeline by Q BioMed Inc, H1 2019

Sepsis – Pipeline by Ra Pharmaceuticals Inc, H1 2019

Sepsis – Pipeline by Recce Ltd, H1 2019

Sepsis – Pipeline by Regeneron Pharmaceuticals Inc, H1 2019

Sepsis – Pipeline by Ribomic Inc, H1 2019

Sepsis – Pipeline by Rimonyx Pharmaceuticals Ltd, H1 2019

Sepsis – Pipeline by SciClone Pharmaceuticals Inc, H1 2019

Sepsis – Pipeline by SetLance srl, H1 2019

Sepsis – Pipeline by Shionogi & Co Ltd, H1 2019

Sepsis – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2019

Sepsis – Pipeline by Syntiron LLC, H1 2019

Sepsis – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Sepsis – Pipeline by Therakind Ltd, H1 2019

Sepsis – Pipeline by Therashock LLC, H1 2019

Sepsis – Pipeline by Vascular BioSciences, H1 2019

Sepsis – Dormant Projects, H1 2019

Sepsis – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Sepsis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Figures

Number of Products under Development for Sepsis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports